PT  - JOURNAL ARTICLE
AU  - Jeremy Petrous
AU  - Kevin Furmaga
TI  - Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts
AID  - 10.1136/bcr-2017-222037
DP  - 2017 Oct 23
TA  - BMJ Case Reports
PG  - bcr-2017-222037
VI  - 2017
4099  - http://casereports.bmj.com/content/2017/bcr-2017-222037.short
4100  - http://casereports.bmj.com/content/2017/bcr-2017-222037.full
AB  - A 59-year-old woman on daily peritoneal dialysis for end-stage renal failure received care at an outpatient psychiatric clinic for her diagnoses that include major depressive disorder, generalised anxiety disorder and insomnia disorder. Although there was partial improvement in the patient’s mood and anxiety symptoms with antidepressant treatment, insomnia remained a persistent complaint despite adequate trials of different sleep medications. The novel hypnotic, suvorexant (Belsomra, Merck & Co.) was then initiated at the recommended bedtime dose of 10 mg and was followed by a 15 mg dose the following night. Within an hour after taking her second suvorexant dose, the severity of patient’s depression symptoms worsened and was accompanied by new onset of suicidal thoughts.